Drugs Containing Excipient (Inactive Ingredient) CITRIC ACID MONOHYDRATE

« Back to Dashboard

Branded drugs containing CITRIC ACID MONOHYDRATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	HYDREA	hydroxyurea	0003-0830	CITRIC ACID MONOHYDRATE
ER Squibb & Sons LLC	DROXIA	hydroxyurea	0003-6336	CITRIC ACID MONOHYDRATE
Merck Sharp & Dohme Corp	ZOCOR	simvastatin	0006-0543	CITRIC ACID MONOHYDRATE
Pharmacia & Upjohn Company LLC	NICOTROL	nicotine	0009-5401	CITRIC ACID MONOHYDRATE

Generic drugs containing CITRIC ACID MONOHYDRATE excipient

Company	Ingredient	NDC	Excipient
ER Squibb & Sons LLC	hydroxyurea	0003-0830	CITRIC ACID MONOHYDRATE
ER Squibb & Sons LLC	elotuzumab	0003-2291	CITRIC ACID MONOHYDRATE
ER Squibb & Sons LLC	hydroxyurea	0003-6336	CITRIC ACID MONOHYDRATE
Merck Sharp & Dohme Corp	simvastatin	0006-0543	CITRIC ACID MONOHYDRATE

Citric Acid Monohydrate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 13, 2026

Citric acid monohydrate is a mature, low-margin pharmaceutical excipient with stable demand and limited patent protection. Its economics are determined primarily by fermentation capacity, agricultural feedstock costs, energy, freight, quality-system compliance, and regional supply concentration. Pharmaceutical demand is comparatively small against food, beverage, detergent, and industrial consumption, but pharmaceutical-grade material commands a premium because of tighter specifications, documentation, traceability, and audit requirements.

Public companies generally do not report citric acid monohydrate revenue separately. The pharmaceutical segment therefore must be assessed through production economics, excipient qualification requirements, supplier concentration, and end-product exposure rather than standalone company revenue.

What is citric acid monohydrate used for in pharmaceutical products?

Citric acid monohydrate is citric acid crystallized with one molecule of water. Its chemical formula is C6H8O7·H2O, and its CAS Registry Number is 5949-29-1.

In pharmaceutical formulations, it is used mainly as:

Function	Pharmaceutical application
pH adjuster	Oral liquids, injectables, topical products, and biologic formulations
Buffer component	Citrate-buffered solutions and reconstituted products
Chelating agent	Control of trace-metal catalyzed oxidation
Effervescent acid	Tablets, powders, and granules with sodium bicarbonate or carbonate
Taste modifier	Oral liquid and chewable formulations
Stabilizer component	Preservation of pH-sensitive active ingredients
Processing aid	Granulation and dissolution performance in selected solid dosage forms

Citric acid monohydrate is commonly used in combination with sodium citrate to create citrate buffers. The monohydrate form is selected where its water content, crystallinity, dissolution behavior, and handling properties fit the formulation process.

The principal commercial distinction is between food-grade, pharmaceutical-grade, and high-purity or compendial-grade material. Pharmaceutical customers typically require compliance with USP-NF, Ph. Eur., or other applicable monographs, together with lot-specific certificates of analysis and supplier qualification.

How large is the pharmaceutical citric acid monohydrate market?

The pharmaceutical portion of the citric acid market is difficult to quantify because producers report citric acid at the company or end-use level, not by hydrate form and pharmaceutical application.

The broader citric acid market is substantially larger than the pharmaceutical segment. Food and beverages remain the dominant uses, followed by detergents, industrial applications, personal care, and animal nutrition. Pharmaceutical-grade citric acid monohydrate is a specialty subsegment within this high-volume commodity market.

A defensible financial view is:

1. Pharmaceutical demand is recurring but relatively small.
2. Food and industrial volumes determine global production economics.
3. Pharmaceutical-grade prices are higher than commodity prices.
4. Pharmaceutical revenue is less sensitive to short-term volume changes but remains exposed to raw-material and logistics inflation.
5. Suppliers with validated pharmaceutical manufacturing and global documentation infrastructure can preserve a premium over non-pharmaceutical suppliers.

Market research firms publish different estimates for the total citric acid market because they use different definitions, geographic scopes, and forecasts. Those estimates should not be treated as direct measures of pharmaceutical-grade citric acid monohydrate revenue.

What is driving the financial trajectory of citric acid monohydrate?

The financial trajectory is stable to moderately growing in volume, with cyclical pricing and margin pressure.

Pharmaceutical demand

Pharmaceutical demand is supported by:

• Continued use in oral liquid, effervescent, and buffer-containing products.
• Growth in generic medicines that use established excipient systems.
• Expansion of contract development and manufacturing organizations.
• Increased use of ready-to-use and single-dose liquid formulations.
• Growth in oral rehydration, pediatric, nutraceutical, and electrolyte products.
• Demand for excipient suppliers with strong traceability and change-control systems.

The strongest growth is likely to come from products using citrate buffering, effervescence, and liquid dosage forms. Demand from conventional tablets and capsules is more stable because citric acid monohydrate is not a universal diluent or binder.

Feedstock and energy costs

Citric acid is produced primarily through fermentation, commonly using carbohydrate feedstocks such as corn-derived glucose, molasses, or other sugar sources. Costs therefore track:

• Corn and glucose prices.
• Sugar and molasses availability.
• Electricity and steam.
• Fermentation yield.
• Water treatment and waste handling.
• Packaging materials.
• Ocean freight and regional distribution.

The cost structure creates a lag between feedstock inflation and pharmaceutical contract-price adjustments. Long-term supply contracts can delay repricing, while spot purchases expose buyers and sellers to faster margin changes.

Chinese production concentration

China is a major global source of citric acid. Large-scale Chinese capacity influences international pricing, export availability, freight patterns, and customer negotiation leverage. This concentration creates a low-cost supply base but also raises exposure to:

• Export restrictions or customs delays.
• Energy rationing.
• Environmental inspections.
• Container availability.
• Regional logistics disruption.
• Customer efforts to dual-source outside China.

European and North American pharmaceutical buyers often maintain secondary suppliers even when the primary source is Chinese because changing an excipient supplier can require technical assessment, stability review, quality documentation, and regulatory evaluation.

Quality premium

The premium for pharmaceutical-grade citric acid monohydrate reflects more than chemical purity. Buyers pay for:

• Compendial testing.
• Microbial control.
• Elemental impurity data.
• Residual solvent and pesticide information where relevant.
• Allergen and GMO statements.
• Nitrosamine and mutagenic impurity assessments where requested.
• Auditability.
• Change notification.
• Supply continuity.
• Regulatory support.

A producer that sells only commodity food-grade material cannot necessarily convert that volume into pharmaceutical revenue without validated processes, suitable documentation, and customer approval.

Which companies supply pharmaceutical-grade citric acid monohydrate?

The competitive market includes multinational specialty-ingredient suppliers, large Chinese fermentation producers, European manufacturers, and regional distributors.

Supplier or supplier group	Competitive position
Jungbunzlauer	Specialty organic acids and pharmaceutical-grade citric acid with strong European quality positioning
ADM and other multinational ingredient companies	Large-scale sourcing, global distribution, and broad customer relationships
RZBC and other Chinese producers	Significant production scale and cost competitiveness
Weifang Ensign and other Chinese producers	High-volume citric acid production and export capability
Gadot Biochemical Industries	Global supply and specialty ingredient distribution
Regional pharmaceutical excipient distributors	Local inventory, regulatory support, and customer qualification assistance

The supplier landscape is fragmented at the distribution level but more concentrated at the manufacturing level. Buyers often qualify one primary manufacturer and one alternate source. Supplier switching is possible, but qualification costs and formulation risk reduce short-term price elasticity.

What regulatory status applies to citric acid monohydrate?

Citric acid monohydrate is an established pharmaceutical excipient rather than an active pharmaceutical ingredient. It is listed in major pharmacopoeial systems and is widely used in FDA-regulated drug products.

Relevant regulatory considerations include:

• USP-NF monograph requirements.
• European Pharmacopoeia requirements.
• FDA Inactive Ingredient Database entries for citric acid or related nomenclature.
• Current Good Manufacturing Practice requirements for drug products.
• Excipient supplier qualification and change control.
• Safety and toxicology data for the intended route and level of use.

FDA’s Inactive Ingredient Database provides precedent for inactive-ingredient use in approved drug products, but it does not replace product-specific formulation, quality, and regulatory review.[1] Manufacturers must confirm that the proposed amount, route, dosage form, and grade are appropriate for the product.

The excipient itself generally does not receive an independent FDA marketing approval. Its regulatory importance arises through the finished drug application, the compendial specification, supplier controls, and product quality documentation.

What patents protect citric acid monohydrate?

Citric acid monohydrate is effectively an off-patent commodity excipient. No commercially important basic composition patent protects the molecule or its monohydrate form.

Patent exposure can still arise in four areas:

1. Manufacturing processes, including fermentation conditions, recovery, crystallization, and purification.
2. Particle engineering, including controlled particle size or morphology.
3. Specialized excipient blends or co-processed materials.
4. Finished pharmaceutical formulations that use citric acid monohydrate.

These rights generally protect a process or a finished dosage form, not the ordinary purchase and use of compendial citric acid monohydrate.

Are there Orange Book listings or Paragraph IV challenges?

Citric acid monohydrate is not an FDA-approved drug product and therefore does not have an Orange Book listing as an active ingredient. It does not have standalone Hatch-Waxman exclusivity, five-year new chemical entity exclusivity, or Paragraph IV litigation.

Paragraph IV litigation can involve a finished drug whose formulation or method of use includes citric acid monohydrate. In that situation, the patent dispute concerns the drug product, formulation, dosing method, or manufacturing process. It does not create exclusivity for citric acid monohydrate as a commodity.

Are there biosimilar risks?

There is no direct biosimilar risk. Citric acid monohydrate is a small-molecule excipient and is not a biologic.

Biologic manufacturing creates indirect demand because citric acid or citrate buffers are used in some protein formulations, but the excipient is not subject to the biosimilar approval pathway. Demand can change if a biologic manufacturer modifies its buffer system or moves from liquid to lyophilized presentation.

What formulation patents use citric acid monohydrate?

Formulation patents may claim:

• A specific citrate buffer concentration.
• A defined pH range.
• An effervescent system.
• A liquid formulation with improved stability.
• A pharmaceutical composition that combines citric acid with a particular active ingredient.
• A controlled-release or reconstitution system.
• A lyophilized biologic or peptide formulation.

These patents can create demand for a particular grade or particle profile, but they rarely prevent other manufacturers from producing standard citric acid monohydrate. Their commercial value depends on the protected drug product, not the excipient alone.

What manufacturing and intellectual-property barriers affect supply?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

A pharmaceutical-grade producer must control:

• Fermentation reproducibility.
• Crystallization and hydrate formation.
• Water content.
• Heavy metals and elemental impurities.
• Microbial contamination.
• Residual process chemicals.
• Cross-contamination.
• Packaging integrity.
• Batch traceability.
• Stability and retest periods.

Citric acid monohydrate is hygroscopic enough that storage and packaging conditions matter. Moisture uptake can affect assay, physical handling, caking, and downstream formulation performance.

Intellectual-property barriers

Process know-how can cover fermentation yield, impurity removal, crystallization control, and waste reduction. These rights are usually less commercially durable than formulation patents because production technology can be designed around alternative process conditions.

The more important barrier is customer qualification. A supplier may have technically equivalent material but still face a long approval cycle because pharmaceutical customers must evaluate quality history, audits, change controls, stability impact, and regulatory filings.

What licensing deals and settlement agreements affect citric acid monohydrate?

No major publicly disclosed licensing program or patent settlement is associated with standard pharmaceutical citric acid monohydrate itself. Commercial arrangements are more likely to involve:

• Distribution agreements.
• Regional supply contracts.
• Dual-source qualification.
• Private-label manufacturing.
• Long-term volume commitments.
• Technical-service agreements.

Settlement agreements may arise in disputes over a finished pharmaceutical product containing citrate, but those agreements generally do not affect open-market access to citric acid monohydrate.

How does citric acid monohydrate compare with citric acid anhydrous?

Attribute	Citric acid monohydrate	Citric acid anhydrous
Crystal water	One molecule of water	No crystal water
Molecular weight	Approximately 210.14 g/mol	Approximately 192.12 g/mol
Typical use	Oral liquids, powders, tablets, buffers	Formulations requiring lower water contribution
Processing issue	Moisture and hydrate control	Lower water contribution but different handling behavior
Regulatory status	Widely compendial	Widely compendial
Substitution	Requires recalculation by molecular weight and water content	Requires formulation and stability review

The two forms are not automatically interchangeable on a one-to-one weight basis. Replacing one with the other can change molar concentration, pH, buffer capacity, water balance, tablet behavior, and stability.

What generic launch risks exist for pharmaceutical citric acid monohydrate?

Generic launch risk is low for the excipient itself and higher for finished products that depend on a qualified supply chain.

Key risks include:

• A single-source excipient qualification.
• Supplier change during regulatory review.
• Variability in particle size or water content.
• Delayed documentation from an overseas producer.
• Import disruption.
• Batch failure caused by microbial or elemental impurity results.
• Finished-product dissolution or stability changes after supplier replacement.

For most generic drug manufacturers, citric acid monohydrate is a manageable input cost. The larger risk is operational disruption, not price escalation. A modest excipient price increase usually has little effect on finished-product gross margin, but an unavailable or unqualified batch can delay production and regulatory release.

What is the revenue exposure for pharmaceutical manufacturers?

Revenue exposure is usually indirect. A drug manufacturer does not typically report sales linked to citric acid monohydrate consumption. The excipient may represent a small fraction of cost of goods sold, especially in high-value products.

Financial exposure increases when:

• The product is a high-volume oral liquid.
• The formulation uses a high concentration of citric acid.
• The product is sold under a low-margin contract.
• The manufacturer has only one approved excipient source.
• The product requires a specialized grade.
• The formulation is difficult to requalify.

For excipient suppliers, pharmaceutical-grade citric acid can improve mix and margin, but the market remains tied to the economics of the much larger commodity citric acid industry.

What is the outlook for citric acid monohydrate through 2030?

The base-case outlook is moderate volume growth, periodic price volatility, and gradual investment in supply-chain resilience.

Period	Expected market condition
2024-2025	Continued demand stability; pricing influenced by feedstock, freight, and Chinese export conditions
2026-2027	More dual sourcing and regional inventory among pharmaceutical buyers
2028-2030	Incremental growth from oral liquids, effervescents, biologic buffers, and specialty formulations

Margin expansion is unlikely to be sustained without product differentiation. Suppliers will need to compete through quality systems, regulatory support, geographic inventory, technical service, and reliable change control rather than through chemical novelty.

Key Takeaways

• Citric acid monohydrate is a mature, off-patent pharmaceutical excipient.
• The pharmaceutical segment is smaller than food, beverage, detergent, and industrial demand.
• Public companies rarely disclose pharmaceutical citric acid revenue separately.
• Feedstock, energy, freight, and Chinese production capacity are the main pricing drivers.
• Pharmaceutical-grade material earns a premium because of documentation, validation, and supply reliability.
• There is no standalone Orange Book, Paragraph IV, biosimilar, or FDA exclusivity pathway for the excipient.
• Formulation and manufacturing patents may affect finished drug products but generally do not restrict commodity supply.
• The principal buyer risk is supply interruption or requalification, not patent infringement.
• The 2024-2030 outlook is stable to moderately positive in volume, with cyclical pricing and limited structural margin expansion.

FAQs

Can citric acid monohydrate be replaced with citric acid anhydrous?

Yes, but the substitution requires recalculation for molecular weight, water content, molar concentration, pH, buffer capacity, and formulation stability. It may also require regulatory assessment.

Is pharmaceutical-grade citric acid monohydrate GMP certified?

The material itself is generally manufactured under quality systems appropriate for pharmaceutical excipients, but "GMP certified" depends on the supplier, facility, audit standard, and customer requirement. Buyers should evaluate the supplier’s quality system and applicable certification documents.

Does citric acid monohydrate affect biologic drug stability?

It can. Citrate buffers influence pH, ionic strength, metal binding, aggregation, oxidation, and protein stability. The effect depends on the biologic, concentration, pH, container, and other excipients.

Is citric acid monohydrate subject to commodity price risk?

Yes. Pharmaceutical-grade contracts are less volatile than spot commodity purchases, but the underlying economics remain exposed to glucose or sugar feedstock, energy, transportation, and global production capacity.

Can a drug manufacturer change its citric acid monohydrate supplier without regulatory filing?

Not automatically. The required action depends on the product application, the approved specification, the supplier qualification strategy, and the effect on formulation and process performance. A supplier change can require comparability testing, stability data, customer approval, or a regulatory submission.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, USP-NF. Rockville, MD: United States Pharmacopeial Convention.
3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Strasbourg, France: Council of Europe.
4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211.
5. International Pharmaceutical Excipients Council. (2017). The IPEC excipient composition guide. IPEC Federation.
6. European Medicines Agency. (2015). Guideline on excipients in the label and package leaflet of medicinal products for human use. EMA.
7. Joint FAO/WHO Expert Committee on Food Additives. (1974). Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents. World Health Organization.